Editorial: The NAFLD-MAFLD conundrum

Editorial: The NAFLD-MAFLD conundrum

Bibliographic Details
Main Authors:	Andrea Dalbeni, Rahul Kumar, Somaya Albhaisi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Endocrinology
Subjects:	MAFLD MASLD NAFLD (non-alcoholic fatty liver disease) liver diabetes mellitus BMI - body mass index
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1267341/full

Similar Items

Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
by: Apichat Kaewdech, et al.
Published: (2024-04-01)

Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
by: Haoxuan Zou, et al.
Published: (2024-07-01)

Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
by: Jin Imai, et al.
Published: (2024-06-01)

MAFLD: How is it different from NAFLD?
by: Cameron Gofton, et al.
Published: (2023-02-01)

COVID-19 and MAFLD/NAFLD: An updated review
by: Ali Nowroozi, et al.
Published: (2023-03-01)

Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options
by: Justyna Śliz, et al.
Published: (2024-07-01)

From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
by: Alexandra Gatzios, et al.
Published: (2022-01-01)

Diet, oxidative stress and MAFLD: a mini review
by: Zenan Hu, et al.
Published: (2025-03-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
by: Andrea Boccatonda, et al.
Published: (2023-03-01)

The myth of the stigma of fatty liver: What does the evidence show?
by: Mariana M. Ramírez-Mejía, et al.
Published: (2024-11-01)

A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies
by: Daniel E. Lefever, et al.
Published: (2022-06-01)

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
by: Reem Abou Assi, et al.
Published: (2021-03-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01)

Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study
by: Xue Bao, et al.
Published: (2024-06-01)

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
by: Ziyan Pan, et al.
Published: (2024-09-01)

Adding to the confusion in more than just the name
by: Jacob George
Published: (2023-10-01)

Targeting leptin/CCL3-CCL4 axes in NAFLD/MAFLD: A novel role for BPF in counteracting thalamic inflammation and white matter degeneration
by: Antonio Cardamone, et al.
Published: (2024-11-01)

Global epidemiology of T2DM in patients with NAFLD or MAFLD: the real situation may be even more serious
by: Yinglan Ji, et al.
Published: (2024-10-01)

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
by: Kamlesh K. Bhopale, et al.
Published: (2023-10-01)

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
by: Atie Moghtadaie, et al.
Published: (2023-09-01)

Identifying advanced MAFLD in a cohort of T2DM and clinical features
by: Ana Maria Sanchez-Bao, et al.
Published: (2023-02-01)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
by: Ming-Lun Yeh, et al.
Published: (2023-10-01)

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
by: Yusuke Johira, et al.
Published: (2023-06-01)

NAFLD is a risk factor for the development of diabetic nephropathy in patients with T2DM
by: Usmani MH, et al.
Published: (2023-05-01)

Diagnostic accuracy of Fatty Liver Index (FLI) for detecting Metabolic Associated Fatty Liver Disease (MAFLD) in adults attending a tertiary care hospital, a cross-sectional study
by: Roshni Vamja, et al.
Published: (2024-12-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Pre-diabetes and cardiovascular risk factors in NAFLD patients: a retrospective comparative analysis
by: Azam Teimouri, et al.
Published: (2025-02-01)

Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score
by: Pimsiri Sripongpun, et al.
Published: (2024-10-01)

Editorial: Multi-organ linkage pathophysiology and therapy for NAFLD and NASH
by: Takefumi Kimura, et al.
Published: (2024-06-01)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
by: Somaya Albhaisi, et al.
Published: (2023-08-01)

A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
by: Adrian Kruszewski, et al.
Published: (2024-07-01)

Comparison of transient elastography and shear wave elastography in patients with MAFLD: A single-center experience
by: Kohla Mohamed Ahmed Samy, et al.
Published: (2024-09-01)

Associations of five dietary indices with metabolic dysfunction-associated steatotic liver disease and liver fibrosis among the United States population
by: Min Xu, et al.
Published: (2024-08-01)

Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
by: Qingfu Dong, et al.
Published: (2023-04-01)

TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
by: Imke Liebold, et al.
Published: (2023-01-01)

Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond
by: Ting Tai, et al.
Published: (2024-10-01)

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis
by: Limin Cao, et al.
Published: (2024-03-01)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
by: Giovanni Targher
Published: (2020-10-01)

Comparison of MAFLD and NAFLD Characteristics in Children
by: Yunfei Xing, et al.
Published: (2023-03-01)